Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 17, 2025
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
GlobeNewswire
·
March 17, 2025
Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareholder value Day One’s OJEMDA™ (tovorafenib) and Zevra’s …
ProHance Releases Global Productivity Benchmarking Report for 2023 & 2024
EIN Presswire
·
March 17, 2025
ProHance releases its 2023-24 Global Productivity Benchmarking Report, offering key insights into workforce efficiency, trends, and industry best practices BENGALURU, KARNATAKA, INDIA, March 17, 2025 /EINPresswire.com/ -- ProHance, a new-age workforce …
Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results
GlobeNewswire
·
March 17, 2025
FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal second quarter ended January 31, 2025, with sequential quarter improvement in revenue, gross …
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
GlobeNewswire
·
March 17, 2025
PARIS and CAMBRIDGE, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering disruptive nanotherapeutic approaches to revolutionize treatment outcomes …
NANOBIOTIX renforce sa visibilité financière en amendant son accord de licence globale pour JNJ-1900 (NBTXR3) qui étend son horizon de trésorerie jusqu’à mi-2026
GlobeNewswire
·
March 17, 2025
PARIS et CAMBRIDGE, Mass., 17 mars 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les …
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 17, 2025
Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected …
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
March 17, 2025
BRISBANE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory …
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
GlobeNewswire
·
March 17, 2025
Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months Leveraged hemophilia A albumin platform to achieve in vivo …
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 17, 2025
GUILFORD, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system— …
OrthoPediatrics Corp. Joins Crossroads Pediatric Device Consortium to Advance Pediatric Medical Device Innovation
GlobeNewswire
·
March 17, 2025
WARSAW, Ind., March 17, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its partnership with the Crossroads …
Nanox to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025
GlobeNewswire
·
March 17, 2025
PETACH TIKVA, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal …
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 17, 2025
Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway extended into 2027 Initiation of the Phase 2 monotherapy …
Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
GlobeNewswire
·
March 17, 2025
Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and …
AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific
GlobeNewswire
·
March 17, 2025
VALENCIA, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it has entered into a new Contract Manufacturing …
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
GlobeNewswire
·
March 17, 2025
SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 25, 2025 at 4:30 pm …
BridgeBio Announces CFO Succession
GlobeNewswire
·
March 17, 2025
PALO ALTO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D. has been appointed …
Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results
GlobeNewswire
·
March 17, 2025
MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a …
A' Mental Health and Wellness Products Design Award Announces Comprehensive Prize Package for 2024
EIN Presswire
·
March 17, 2025
A' Mental Health and Wellness Products Design Award unveils extensive recognition package aimed at advancing therapeutic excellence and innovation COMO, CO, ITALY, March 17, 2025 /EINPresswire.com/ -- The A' Mental Health and Wellness Products Design …
Pharmaceutical Warehousing Market Poised for Global Growth: Expected to Exceed USD 39 Billion by 2032, Grow at 4.7% CAGR
EIN Presswire
·
March 17, 2025
Growth in the pharmaceutical sector, increase in demand from the e-commerce industry, and surge in demand for reverse logistics drive the growth of the market. OREGON, DE, UNITED STATES, March 17, 2025 /EINPresswire.com/ -- According to a new report …
Biomedical Textiles Market Existing and Upcoming Developments Forecast to 2032
EIN Presswire
·
March 17, 2025
Increasing investments in medical treatments and technologies are fueling demand for biomedical textiles. WILMINGTON, DE, UNITED STATES, March 17, 2025 /EINPresswire.com/ -- The global biomedical textiles market is experiencing significant growth, …